NasdaqCM:AGEN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. More Details


Snowflake Analysis

Limited growth with imperfect balance sheet.

Share Price & News

How has Agenus's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AGEN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-17.2%

AGEN

-1.0%

US Biotechs

-3.1%

US Market


1 Year Return

49.7%

AGEN

31.3%

US Biotechs

12.7%

US Market

Return vs Industry: AGEN exceeded the US Biotechs industry which returned 32% over the past year.

Return vs Market: AGEN exceeded the US Market which returned 12.9% over the past year.


Shareholder returns

AGENIndustryMarket
7 Day-17.2%-1.0%-3.1%
30 Day7.1%-0.5%-2.9%
90 Day1.4%-2.2%8.2%
1 Year49.7%49.7%33.6%31.3%15.3%12.7%
3 Year-3.0%-3.0%17.6%11.9%37.8%28.5%
5 Year-8.0%-8.0%27.2%18.2%90.9%69.4%

Price Volatility Vs. Market

How volatile is Agenus's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Agenus undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Agenus is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Agenus has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Agenus forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

10.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AGEN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AGEN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AGEN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AGEN's revenue (34% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: AGEN's revenue (34% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AGEN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Agenus performed over the past 5 years?

-8.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AGEN is currently unprofitable.

Growing Profit Margin: AGEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AGEN is unprofitable, and losses have increased over the past 5 years at a rate of 8.8% per year.

Accelerating Growth: Unable to compare AGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: AGEN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Agenus's financial position?


Financial Position Analysis

Short Term Liabilities: AGEN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: AGEN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: AGEN has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: AGEN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AGEN has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: AGEN is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Agenus's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AGEN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Garo Armen (67 yo)

26.67yrs

Tenure

US$9,937,038

Compensation

Dr. Garo H. Armen, Ph.D., founded Agenus Inc. in 1994 and has been its Chief Executive Officer since 1994. Dr. Armen serves as an Executive Chairman of Agenus Inc. He has been an Executive Director of Agen ...


CEO Compensation Analysis

Compensation vs Market: Garo's total compensation ($USD9.94M) is above average for companies of similar size in the US market ($USD2.96M).

Compensation vs Earnings: Garo's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Garo Armen
Founder26.67yrsUS$9.94m0.66%
$ 5.2m
Jennifer Buell
President & COO0.67yrUS$2.39m0.019%
$ 150.8k
Evan Kearns
VP, Chief Compliance Officer2.17yrsUS$1.61m0.0070%
$ 54.6k
Christine Klaskin
VP of Finance1.08yrsUS$497.48kno data
Regina Grebla
VP of Investor Relations & Communicationsno datano datano data
Ozer Baysal
Chief Commercial Officer & Head of HR3.17yrsUS$461.73kno data
John Castle
Head of Translational Medicine & Bioinformatics2.67yrsno datano data
Paulo Moreira
Global Head of Clinical Operations1.5yrsno datano data
Dhan Chand
Scientific Director & Head of Drug Discoveryno datano datano data
Don Vidic
VP & Head of Commercial1.17yrsno datano data
Mark Exley
Vice President of Cellular Immunologyno datano datano data
Julie DeSander
Vice President of Business Development & Alliance Management2.67yrsno datano data

2.2yrs

Average Tenure

54yo

Average Age

Experienced Management: AGEN's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Garo Armen
Founder26.67yrsUS$9.94m0.66%
$ 5.2m
Paul Clark
Director0.083yrno data0.039%
$ 299.5k
Ulf Wiinberg
Independent Director4.33yrsUS$559.92k0.045%
$ 347.8k
Wadih Jordan
Independent Director17.5yrsUS$457.14k0%
$ 0
Timothy Wright
Independent Lead Director11.67yrsUS$562.14k0.029%
$ 227.9k
Brian Corvese
Independent Director13.5yrsUS$662.14k0.038%
$ 294.5k
Allison Jeynes-Ellis
Director1.83yrsUS$407.94k0.027%
$ 208.7k

8.0yrs

Average Tenure

62yo

Average Age

Experienced Board: AGEN's board of directors are considered experienced (8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.6%.


Top Shareholders

Company Information

Agenus Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Agenus Inc.
  • Ticker: AGEN
  • Exchange: NasdaqCM
  • Founded: 1994
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$775.962m
  • Shares outstanding: 183.44m
  • Website: https://agenusbio.com

Number of Employees


Location

  • Agenus Inc.
  • 3 Forbes Road
  • Lexington
  • Massachusetts
  • 02421-7305
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AGENNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2000
AJ81DB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2000

Biography

Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an anti ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/23 05:56
End of Day Share Price2020/09/22 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.